Clinical Trials Logo
  1. Home
  2. Endstage Renal Disease
  3. NCT02977117

The Effect of Increasing Dialysate Magnesium on Calcification Propensity in Subjects on Haemodialysis

Endstage Renal Disease Clinical Trial

Official title:
The Effect of Increasing Dialysate Magnesium on Serum Calcification Propensity in Subjects With End-Stage Renal Disease Treated With Haemodialysis - A Randomised Clinical Trial

Clinical Trial Summary

The purpose of this trial is to examine the effect of increasing dialyse magnesium on serum calcification propensity in subjects with end-stage renal disease treated with haemodialysis.

Clinical Trial Description

Patients with end-stage renal disease (ESRD) have a 20-fold increased risk of cardiovascular mortality compared to the general population. Arterial stiffness, likely due to vascular calcification (VC), has been shown to predict cardiovascular mortality in ESRD. Serum calcification propensity (T50) is a novel biomarker, which is believed to reflect the propensity toward ectopic calcification (e.g. VC). Increasing serum magnesium (sMg) should increase T50, which might in turn reduce the formation of VC in patients with ESRD. A cheap and easy way of achieving this would be to increase the concentration of Mg in the dialysate (dMg) of patients with ESRD treated with haemodialysis (HD).

The investigators wish to conduct a randomised controlled double-blind clinical trial to examine whether increasing dMg will improve T50 in subjects with ESRD treated with HD. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02977117
Study type Interventional
Source Nordsjaellands Hospital
Contact
Status Completed
Phase Phase 2
Start date December 2016
Completion date June 2017
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03023748 - Intravenous Paricalcitol in Chronic Hemodialysis Patients Phase 4
Terminated NCT00776191 - Randomized Multicenter Cross-over Study to Compare the Effect of Physioneal 35 to 40 on the Protein Metabolism Phase 4
Completed NCT00745914 - Peroxisome Proliferator-Activated Receptor-gamma (PPAR-gamma) Agonist in Diabetic End-Stage Renal Disease Patients N/A
Completed NCT02981706 - Comparison of AVF Versus AVG in Elderly Patients Starting Dialysis N/A
Completed NCT02946229 - Data Collection for Next Generation Ultrasound Technology Development N/A
Completed NCT02966028 - Effect of SNF472 on Progression of Cardiovascular Calcification in End-Stage-Renal-Disease (ESRD) Patients on Hemodialysis (HD) Phase 2
Completed NCT02976246 - Effect of Vitamin K2 (MK7) on Cardiovascular and Bone Disease in Dialysis Patients Phase 4
Recruiting NCT02957877 - LMWH Infusion as Anticoagulation for Home HD Phase 4
Completed NCT00745719 - Parathyroidectomy in Endstage Renal Disease N/A
Completed NCT03010072 - The Effect of Phosphate Lowering Using Sucroferric Oxyhydroxide (PA21) on Calcification Propensity of Serum Phase 2
Recruiting NCT03020303 - Aldosterone bloCkade for Health Improvement EValuation in End-stage Renal Disease Phase 3
Completed NCT00745589 - Sevelamer Hydrochloride in Peritoneal Dialysis Patients N/A
Not yet recruiting NCT02976688 - Effects of Short-chain Fatty Acids on Inflammatory and Metabolic Parameters in Maintenance Hemodialysis Phase 2/Phase 3
Completed NCT02970201 - Improving Adherence in Renal Dialysis Patients Through Electronic Interventions N/A
Withdrawn NCT00502268 - Vitamin D and Carboxy PTH Fragments in Coronary Calcification Phase 4
Completed NCT02207153 - Risk Assessment by Cardiovascular Biomarkers in Chronic Dialysis Patients
Completed NCT02866214 - Effect of Febuxostat on Endothelial Dysfunction in Hemodialysis Patients. Phase 2/Phase 3
Not yet recruiting NCT03054454 - A Podiatry Led MDT Intervention to Reduce the Burden of Foot Disease in Patients With End Stage Kidney Failure N/A